2022
DOI: 10.1038/s41598-022-25811-0
|View full text |Cite
|
Sign up to set email alerts
|

DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularization

Abstract: Neovascularization is a prominent cause of irreversible blindness in a variety of ocular diseases. Current therapies for pathological neovascularization are concentrated on the suppression of vascular endothelial growth factors (VEGF). Despite the remarkable efficacy of anti-VEGF drugs, several problems still exist, including ocular complications and drug resistance. Thus, it is still required to design novel drugs for anti-angiogenic treatment. This study aimed to investigate the anti-angiogenic effects of a … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 40 publications
0
1
0
Order By: Relevance
“…Anti-VEGF drugs may affect these underlying pathophysiological processes differently, and more studies on drug-specific phenotypic changes after drug use in PDR patients are necessary. VEGF in PDR controls angiogenesis through the VEGFR1 and VEGFR2 signal pathways [10] , the latter being the main receptor for VEGF-induced neoangiogenesis and permeability-enhancing effects [11] . The aflibercept selected in this experiment is a chimeric receptor consisting of VEGF receptor 1 (VEGFR1) and VEGFR2 binding domains, which binds with high affinity to VEGF-A, VEGF-B, and placental growth factor.…”
Section: Ppi Network Highlights Anti-vegf Treatment Responsementioning
confidence: 99%
“…Anti-VEGF drugs may affect these underlying pathophysiological processes differently, and more studies on drug-specific phenotypic changes after drug use in PDR patients are necessary. VEGF in PDR controls angiogenesis through the VEGFR1 and VEGFR2 signal pathways [10] , the latter being the main receptor for VEGF-induced neoangiogenesis and permeability-enhancing effects [11] . The aflibercept selected in this experiment is a chimeric receptor consisting of VEGF receptor 1 (VEGFR1) and VEGFR2 binding domains, which binds with high affinity to VEGF-A, VEGF-B, and placental growth factor.…”
Section: Ppi Network Highlights Anti-vegf Treatment Responsementioning
confidence: 99%